Outcome of surgical and radiation therapy treatment of grade II meningiomas: A single institution experience

Bongkot Jia-Mahasap; Salita Angkurawaranon; Songkiet Suwansirikul; Somvilai Chakrabandhu; Pitchayaponne Klunklin; Wimrak Onchan; Patumrat Sripan; Imjai Chitapanarux

Authors

Bongkot Jia-Mahasap Department of Radiology, Faculty of Medicine, Chiang Mai University, Thailand
Salita Angkurawaranon Department of Radiology, Faculty of Medicine, Chiang Mai University, Thailand
Songkiet Suwansirikul Department of Pathology, Faculty of Medicine, Chiang Mai University, Thailand
Somvilai Chakrabandhu Department of Radiology, Faculty of Medicine, Chiang Mai University, Thailand
Pitchayaponne Klunklin Department of Radiology, Faculty of Medicine, Chiang Mai University, Thailand
Wimrak Onchan Department of Radiology, Faculty of Medicine, Chiang Mai University, Thailand
Patumrat Sripan Department of Radiology, Faculty of Medicine, Chiang Mai University, Thailand
Imjai Chitapanarux Department of Radiology, Faculty of Medicine, Chiang Mai University, Thailand

Keywords:

WHO grade II meningiomas, outcome, adjuvant radiation therapy

Abstract

Objective To evaluate local control and survival rates with two different treatment modalities: surgery alone and surgery plus adjuvant radiation therapy (RT).

Methods Cases of 104 patients diagnosed with grade II meningiomas between 2004 and 2014 were retrospectively reviewed. Of those, 68 patients had complete medical records. For inclusion in this study, we required a follow-up period of more than 2 years. Age at diagnosis, initial tumor size, tumor location, extent of resection and adjuvant RT were categorized to identify possible parame-ters that may have affected the outcome of this disease.

Result Thirty-seven patients (54%) received surgery alone while 31 patients (46%) received
adjuvant RT. The 2-year and 5-year rates of local control (LC) were 94% and 87%, respectively. No correlation was found between other parameters and recurrence of tumors. Patients in our study who received adjuvant RT had significant lower overall survival rate (p=0.044). The 2-year overall survival (OS) was 99% and 5-year OS was 93%.

Conclusion Tumor control and survival were found to be excellent in this retrospective study.
Adjuvant RT did not influence local control, but was statistically associated with lower survival rates. Further prospective study should be performed to clarify the management of grade II meningiomas.

References

1. Hammouche S, Clark S, Wong AH, Eldridge P, Farah JO. Long-term survival analysis of atypical meningiomas: survival rates, prognostic factors, operative and radiotherapy treatment. Acta Neurochirurgica. 2014;156:1475-81.
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathologica. 2007;114:97-109.
3. Lee KD, DePowell JJ, Air EL, Dwivedi AK, Kendler A, McPherson CM. Atypical meningiomas: is postoperative radiotherapy indicated? Neurosurgical Focus. 2013;35:E15.
4. Press RH, Prabhu RS, Appin CL, Brat DJ, Shu HK, Hadjipanayis C, et al. Outcomes and patterns of failure for grade 2 meningioma treated with reduced-margin intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2014;88:1004-10
5. Yang S-Y, Park C-K, Park S-H, Kim DG, Chung YS, Jung H-W. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry. 2008;79:574-80.
6. Aghi MK, Carter BS, Cosgrove GR, Ojemann RG, Amin-Hanjani S, Martuza RL, et al. Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery. 2009;64:56-60; discussion
7. Kaur G, Sayegh ET, Larson A, Bloch O, Madden M, Sun MZ, et al. Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review. Neuro-Oncology. 2014;16:628-36.
8. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957;20:22-39.
9. Detti B, Scoccianti S, Di Cataldo V, Monteleone E, Cipressi S, Bordi L, et al. Atypical and malignant meningioma: outcome and prognostic factors in 68 irradiated patients. J Neurooncol. 2013;115:421-7.
10. Walcott BP, Nahed BV, Brastianos PK, Loeffler JS. Radiation Treatment for WHO Grade II and III Meningiomas. Frontiers in Oncology. 2013;3:227.
11. Milosevic MF, Frost PJ, Laperriere NJ, Wong CS, Simpson WJ. Radiotherapy for atypical or malignant intracranial meningioma. Int J Radiat Oncol Biol Phys. 1996; 34:817-22.
12. Milker-Zabel S, Zabel A, Schulz-Ertner D, Schlegel W, Wannenmacher M, Debus J. Fractionated stereotactic radiotherapy in patients with benign or atypical intracranial meningioma: long-term experience and prognostic factors. Int J Radiat Oncol Biol Phys. 2005;61:809-16.
13. Rogers L, Zhang P, Vogelbaum MA, Perry A, Ashby LS, Modi JM, et al. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg. 2017;6:1-13.
14. Adeberg S, Hartmann C, Welzel T, Rieken S, Habermehl D, von Deimling A, et al. Long-term outcome after radiotherapy in patients with atypical and malignant meningiomas--clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy. Int J Radiat Oncol Biol Phys. 2012;83:859-64.
15. Park HJ, Kang HC, Kim IH, Park SH, Kim DG, Park CK, et al. The role of adjuvant radiotherapy in atypical meningioma. J Neurooncol. 2013;115:241-7.
16. Pasquier D, Bijmolt S, Veninga T, Rezvoy N, Villa S, Krengli M, et al. Atypical and malignant meningioma: outcome and prognostic factors in 119 irradiated patients. A multicenter, retrospective study of the Rare Cancer Network. Int J Radiat Oncol Biol Phys. 2008;71:1388-93.
17. Yoon H, Mehta MP, Perumal K, Helenowski IB, Chappell RJ, Akture E, et al. Atypical meningioma: randomized trials are required to resolve contradictory retrospective results regarding the role of adjuvant radiotherapy. J Cancer Res Ther. 2015;11:59-66.